We included a total of 10 038 patients with T2D newly receiving SGLT2 inhibitors and 1077 newly receiving GLP-1 RAs based on the study inclusion and exclusion criteria and IPTW with 5% trimming approach (eFigure in the Supplement). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.